CA Stock MarketDetailed Quotes
BUX Biomark Diagnostics Inc
- 0.190
- -0.010-5.00%
15min DelayMarket Closed Dec 23 14:59 ET
17.27MMarket Cap-9.50P/E (TTM)
0.190High0.190Low9.00KVolume0.190Open0.200Pre Close1.71KTurnover0.31552wk High0.01%Turnover Ratio90.89MShares0.18052wk Low-0.02EPS TTM17.27MFloat Cap1.020Historical HighLossP/E (Static)90.89MShs Float0.025Historical Low-0.02EPS LYR0.00%Amplitude--Dividend TTM-17.27P/B1Lot Size--Div YieldTTM
Biomark Diagnostics Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -1,002.24%-130.64K | -28.39%-320.69K | -7.45%-982.52K | -22.39%-214.47K | -227.80%-506.43K | 95.78%-11.85K | 17.84%-249.77K | 24.05%-914.42K | 63.56%-175.23K | -168.96%-154.5K |
| Net income from continuing operations | -160.05%-547.3K | -48.80%-623.28K | 22.52%-1.43M | 21.97%-391.31K | -3.32%-406.76K | 60.13%-210.46K | 0.07%-418.86K | -26.71%-1.84M | 31.29%-501.51K | -53.26%-393.7K |
| Depreciation and amortization | -35.74%58.17K | -43.80%57.76K | 1.81%393.17K | -1.84%100.85K | 9.74%99.04K | -6.30%90.51K | 6.38%102.77K | 115.00%386.2K | -21.15%102.74K | 104.44%90.25K |
| Remuneration paid in stock | 243.73%111.54K | 485.43%209.39K | -77.09%75.48K | -239.77%-8.53K | -87.13%15.8K | -83.83%32.45K | --35.77K | --329.53K | --6.1K | --122.71K |
| Other non cashItems | 22.20%16.56K | 22.45%18.9K | -15.84%62.66K | -76.86%17.5K | 549.85%16.17K | 168.19%13.55K | -30.75%15.44K | 168.42%74.46K | 386.71%75.64K | -136.41%-3.6K |
| Change In working capital | 271.05%230.4K | 9.46%16.54K | -162.81%-86.45K | -52.73%67.02K | -872.98%-230.67K | 305.36%62.09K | 500.45%15.11K | 222.97%137.63K | 37.49%141.8K | -79.48%29.84K |
| -Change in receivables | -530.81%-36.45K | 21.20%12.01K | -118.12%-8.65K | 136.01%4.43K | -364.19%-17.22K | -174.23%-5.78K | -82.19%9.91K | 186.89%47.76K | 75.58%-12.3K | 606.83%6.52K |
| -Change in payables and accrued expense | 293.16%266.85K | -12.91%4.53K | -186.57%-77.8K | -59.83%60.57K | -1,006.47%-211.43K | 373.72%67.87K | 108.75%5.2K | -20.87%89.87K | 36.35%150.76K | -18.53%23.33K |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -1,002.24%-130.64K | -28.39%-320.69K | -7.45%-982.52K | -22.39%-214.47K | -227.80%-506.43K | 95.78%-11.85K | 17.84%-249.77K | 24.05%-914.42K | 63.56%-175.23K | -168.96%-154.5K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -2.51K | 17.08%-4.39K | -123,500.00%-1.24K | -190.37%-2.2K | -95,800.00%-957 | 0 | 91.05%-5.3K | -1 | 98.72%-758 |
| Net PPE purchase and sale | --0 | ---2.51K | 17.08%-4.39K | -123,500.00%-1.24K | -190.37%-2.2K | -95,800.00%-957 | --0 | 91.05%-5.3K | ---1 | 98.72%-758 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | ---2.51K | 17.08%-4.39K | -123,500.00%-1.24K | -190.37%-2.2K | -95,800.00%-957 | --0 | 91.05%-5.3K | ---1 | 98.72%-758 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 297.61%23.92K | -12.79%307.81K | 75.95%1.07M | -47.59%59.42K | 410.54%653.22K | -92.18%6.02K | 21.38%352.97K | -20.71%609.05K | -83.43%113.36K | 253.74%127.95K |
| Net issuance payments of debt | 56.18%-102.88K | -1.20%-102.88K | -144.23%-732.64K | -84.38%-295.13K | -27.39%-101.08K | 59.00%-234.76K | -119.86%-101.66K | -86.58%-299.99K | -349.98%-160.07K | 63.85%-79.35K |
| Net common stock issuance | ---- | ---- | 155.62%1.54M | --0 | ---- | ---- | ---- | --603.2K | --0 | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -84.04%37.5K | --0 | --0 |
| Net other financing activities | -47.34%126.8K | -9.67%410.69K | -2.21%262.4K | 29.67%354.55K | -479.92%-787.57K | 420.01%240.78K | 275.74%454.64K | -61.33%268.34K | -55.92%273.43K | 52.09%207.3K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 297.61%23.92K | -12.79%307.81K | 75.95%1.07M | -47.59%59.42K | 410.54%653.22K | -92.18%6.02K | 21.38%352.97K | -20.71%609.05K | -83.43%113.36K | 253.74%127.95K |
| Net cash flow | ||||||||||
| Beginning cash position | -19.33%141.36K | 117.60%156.75K | -81.18%72.04K | 133.78%313.03K | 4.49%168.45K | -51.98%175.24K | -81.18%72.04K | -56.40%382.71K | -25.32%133.9K | -57.48%161.21K |
| Current changes in cash | -1,471.16%-106.71K | -114.91%-15.39K | 127.27%84.71K | -152.63%-156.28K | 629.49%144.59K | 96.67%-6.79K | 681.24%103.2K | 37.23%-310.67K | -130.41%-61.86K | 86.34%-27.31K |
| End cash Position | -79.43%34.65K | -19.33%141.36K | 117.60%156.75K | 117.60%156.75K | 133.78%313.03K | 4.49%168.45K | -51.98%175.24K | -81.18%72.04K | -81.18%72.04K | -25.32%133.9K |
| Free cash from | -919.88%-130.64K | -29.40%-323.2K | -7.31%-986.92K | -23.10%-215.7K | -227.61%-508.63K | 95.44%-12.81K | 19.05%-249.77K | 27.19%-919.72K | 63.56%-175.23K | -33.10%-155.25K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Price
% Chg
No Data